Get the Stockscreener App
37.32
4.45%
-1.74
After Hours:
37.32
Collegium Pharmaceutical Inc stock is traded at $37.32, with a volume of 412.94K.
It is down -4.45% in the last 24 hours and down -1.45% over the past month.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
See More
Previous Close:
$39.06
Open:
$38.86
24h Volume:
412.94K
Relative Volume:
1.13
Market Cap:
$1.18B
Revenue:
$566.77M
Net Income/Loss:
$48.16M
P/E Ratio:
31.36
EPS:
1.19
Net Cash Flow:
$274.29M
1W Performance:
-2.61%
1M Performance:
-1.45%
6M Performance:
+25.95%
1Y Performance:
+2.16%
1-Day Range:
$37.26
$38.86
1-Week Range:
$37.09
$39.12
52-Week Range:
$23.23
$42.29
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Name
Collegium Pharmaceutical Inc
Sector
Phone
781-713-3699
Address
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
37.32 | 1.19B | 566.77M | 48.16M | 274.29M | 1.19 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | Needham | Hold → Buy |
| Jul-30-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-07-24 | Upgrade | Jefferies | Hold → Buy |
| May-10-24 | Downgrade | Needham | Buy → Hold |
| May-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-25-23 | Reiterated | Needham | Buy |
| May-02-23 | Resumed | Jefferies | Buy |
| Aug-08-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-15-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-06-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Jul-14-20 | Initiated | BWS Financial | Sell |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Feb-19-20 | Resumed | Jefferies | Buy |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-03-19 | Resumed | H.C. Wainwright | Buy |
| Apr-12-19 | Resumed | Janney | Buy |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Jan-16-19 | Reiterated | Needham | Buy |
| Mar-08-18 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-18 | Reiterated | Needham | Buy |
| Dec-05-17 | Reiterated | Needham | Buy |
| Sep-11-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Reiterated | Needham | Buy |
| Sep-13-16 | Initiated | Gabelli & Co | Buy |
| Jun-01-15 | Initiated | Jefferies | Buy |
| Jun-01-15 | Initiated | Needham | Buy |
| Jun-01-15 | Initiated | Piper Jaffray | Overweight |
View All
Collegium Pharmaceutical Inc Stock (COLL) Latest News
Russell Investments Group Ltd. Sells 11,057 Shares of Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Insider Selling: Collegium Pharmaceutical (NASDAQ:COLL) EVP Sells 17,478 Shares of Stock - MarketBeat
Collegium Pharmaceutical at Morgan Stanley Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Is It Too Early to Call Recovery in Collegium Pharmaceutical Inc.New Guidance & Low Risk Profit Maximizing Plans - beatles.ru
What earnings revisions data tells us about Collegium Pharmaceutical Inc.July 2025 Trends & Community Verified Trade Signals - Newser
Executive VP & Chief Medical Officer Thomas Smith Sold A Bunch Of Shares In Collegium Pharmaceutical - 富途牛牛
Will Collegium Pharmaceutical Inc. stock hit new highs in YEAR2025 Analyst Calls & Smart Investment Allocation Tips - خودرو بانک
Collegium Pharmaceutical, Inc. (COLL) to Present 9 Pain Studies at PAINWeek 2025 - MSN
Collegium Pharmaceutical Inc. stock chart pattern explainedTrade Exit Summary & Weekly High Return Forecasts - Newser
What MACD signals say about Collegium Pharmaceutical Inc.2025 Short Interest & Comprehensive Market Scan Insights - Newser
Will a bounce in Collegium Pharmaceutical Inc. offer an exitStop Loss & Daily Entry Point Trade Alerts - Newser
Hsbc Holdings PLC Has $703,000 Stock Holdings in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Will Collegium Pharmaceutical Inc. rebound enough to break even2025 Momentum Check & Free Expert Verified Stock Movement Alerts - Newser
What data driven models say about Collegium Pharmaceutical Inc.’s futurePortfolio Update Summary & AI Based Buy and Sell Signals - Newser
Chart based analysis of Collegium Pharmaceutical Inc. trendsEarnings Recap Summary & Short-Term Swing Trade Alerts - Newser
Risk adjusted return profile for Collegium Pharmaceutical Inc. analyzedJuly 2025 Closing Moves & Stepwise Trade Execution Plans - Newser
Is Collegium Pharmaceutical Inc. forming a bottoming base2025 Market Outlook & AI Forecast Swing Trade Picks - Newser
Analyzing Collegium Pharmaceutical Inc. with risk reward ratio chartsDividend Hike & AI Enhanced Trade Execution Alerts - Newser
Multi factor analysis applied to Collegium Pharmaceutical Inc.Market Growth Report & Free Long-Term Investment Growth Plans - Newser
Trend analysis for Collegium Pharmaceutical Inc. this weekWeekly Profit Report & Technical Buy Zone Confirmations - Newser
Can Collegium Pharmaceutical Inc. deliver alphaJuly 2025 Volume & Low Volatility Stock Recommendations - khodrobank.com
What’s the recovery path for long term holders of Collegium Pharmaceutical Inc.2025 Big Picture & AI Powered Trade Plan Recommendations - Newser
89,566 Shares in Collegium Pharmaceutical, Inc. $COLL Bought by Nuveen LLC - MarketBeat
Is Collegium Pharmaceutical Inc. stock poised for growthWeekly Trade Recap & Consistent Income Trade Recommendations - Newser
Using data models to predict Collegium Pharmaceutical Inc. stock movement2025 Market Trends & Safe Swing Trade Setups - Newser
Is Collegium Pharmaceutical Inc. stock undervalued right nowJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - خودرو بانک
Leading the way in pharma finance: Collegium CFO Colleen Tupper shares her vision - BioXconomy
Is Collegium Pharmaceutical Inc. a good stock for dollar cost averaging2025 Top Gainers & Weekly Breakout Watchlists - خودرو بانک
Can swing trading help recover from Collegium Pharmaceutical Inc. lossesWeekly Market Report & Weekly Top Gainers Alerts - Newser
Evaluating Collegium Pharmaceutical Inc. with trendline analysisLong Setup & Weekly Setup with ROI Potential - Newser
Will Collegium Pharmaceutical Inc. stock go up soon2025 Major Catalysts & Smart Allocation Stock Tips - Newser
Full technical analysis of Collegium Pharmaceutical Inc. stockWeekly Investment Summary & Free High Accuracy Swing Entry Alerts - Newser
Collegium Pharmaceutical Inc. stock prediction for this week2025 Market Overview & Daily Oversold Bounce Ideas - Newser
Campbell & CO Investment Adviser LLC Buys New Shares in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
How to build a dashboard for Collegium Pharmaceutical Inc. stockJuly 2025 Intraday Action & Daily Entry Point Alerts - Newser
Developing predictive dashboards with Collegium Pharmaceutical Inc. dataJuly 2025 Retail & Verified Momentum Stock Watchlist - Newser
Collegium Pharmaceutical Inc Stock (COLL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):